Abstract 1392: Integrative biomarker analysis of regorafenib plus nivolumab (RegoNivo) in unresectable hepatocellular carcinoma (uHCC): A multicenter phase 2 RENOBATE trial
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1392
Abstract: Regorafenib plus nivolumab (RegoNivo) combination has shown promising anti-cancer activity in multiple cancer types. REBNOBATE trial is a single-arm multicenter phase 2 trial of first-line RegoNivo in patients (pts) with uHCC (NCT04310709). Here we report… read more here.
Keywords: biomarker; regorafenib plus; trial; analysis ... See more keywords
A phase I/II study of regorafenib (R) plus avelumab (A) in digestive tumors.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps3125
Abstract: TPS3125Background: Several preclinical studies have shown that simultaneous blockade of programmed death(PD) 1/PD-L1 and neoangiogenesis induces synergistic anti-tumour effect in vivo. R is a multi... read more here.
Keywords: study regorafenib; avelumab digestive; digestive tumors; regorafenib plus ... See more keywords
Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.838870
Abstract: Background Regorafenib improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we report the treatment patterns of regorafenib in the third- or late-line setting for mCRC in… read more here.
Keywords: regorafenib plus; refractory metastatic; metastatic colorectal; pfs ... See more keywords